ZA202107931B
(en )
2023-10-25
Anti-tau antibodies and methods of use
PH12020550781A1
(en )
2021-08-02
Anti-jagged1 antibodies and methods of use
PH12017500877B1
(en )
2017-11-06
ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12017500861A1
(en )
2017-11-06
Anti-interleukin-33 antibodies and uses thereof
PH12016501894B1
(en )
2017-01-09
Anti-ox40 antibodies and methods of use
MX2017005920A
(en )
2017-06-27
Anti-tim3 antibodies and methods of use.
PH12018500711A1
(en )
2018-10-15
Anti-pd1 antibodies and methods of use
PH12017500322A1
(en )
2017-07-10
Anti-her2 antibodies and immunoconjugates
MA40579A
(en )
2016-03-17
Anti-cll-1 antibodies and immunoconjugates
CR20230163A
(en )
2023-07-06
Anti-tau antibodies and methods of use
MX2015012326A
(en )
2016-03-08
Anti-crth2 antibodies and their use.
MX2017010667A
(en )
2018-08-15
Anti-pvrig antibodies and methods of use.
MY176285A
(en )
2020-07-27
Anti-fcrh5 antibodies
WO2018081648A8
(en )
2019-04-11
Anti-mic antibodies and methods of use
MX2016015162A
(en )
2017-03-03
Anti-gpc3 antibodies and immunoconjugates.
MX2019006330A
(en )
2019-09-26
Anti-tau antibodies and methods of their use.
MX2016004853A
(en )
2016-07-19
ANTI-Ly6E ANTIBODIES AND METHODS OF USE.
MX2016016233A
(en )
2017-03-31
Anti-lgr5 antibodies and uses thereof.
MX2016015280A
(en )
2017-03-03
Anti-brdu antibodies and methods of use.
MX2015010789A
(en )
2015-11-26
Anti-mcsp antibodies.
NZ744340A
(en )
2020-01-31
Anti-jagged1 antibodies and methods of use